AbbVie faced a major challenge as Humira sales plummeted after biosimilars entered the market, dropping from $21 billion annually to $688 million in Q1 2026. However, the company successfully pivoted with strong growth in newer drugs Skyrizi and Rinvoq, generating $4.483 billion and $2.119 billion respectively in Q1 2026. The 2020 Allergan acquisition added valuable products like Botox and Juvederm, boosting revenue to $61.16 billion in 2025. AbbVie raised its 2026 earnings guidance and has delivered a 400% return over 10 years, outperforming the S&P 500. Investors see potential in AbbVie's pipeline and dividend yield, though risks remain from future patent expirations starting in 2028.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
